Gout is a chronic intermittent arthritis that is becoming increasingly prevalent around the world. Gout is caused by the deposition of Monosodium Urate crystals in articular and extra articular locations. Hyperuricemia is the main precondition for this phenomenon. Gout attacks are characterized by pain and swelling. This paper will cover the epidemiology, the pathophysiology, the diagnosis and the clinical presentations of Gout, and mainly the 2 different pharmaceutical goals of Gout treatment. The first goal of Gout treatment is to mitigate acute attacks by using various anti-inflammatory medications such as NSAIDs, Corticosteroids, Colchicine and anti-IL-1β biological therapy. The second aim of treatment is to lower urate levels in serum by using medications such as Xanthine Oxidase inhibitors, Uricosuric agents and Uricase replacements. Although the current treatment options are effective, research into biological and immuno-therapy options offer glimpses of future improvement in Gout treatment and its underlying causes.